These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30412117)

  • 1. Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: Association with pathologic complete response.
    Dong JM; Wang HX; Zhong XF; Xu K; Bian J; Feng Y; Chen L; Zhang L; Wang X; Ma DJ; Wang B
    Medicine (Baltimore); 2018 Oct; 97(43):e12965. PubMed ID: 30412117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
    You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
    Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
    Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy.
    Rella R; Bufi E; Belli P; Petta F; Serra T; Masiello V; Scrofani AR; Barone R; Orlandi A; Valentini V; Manfredi R
    Diagn Interv Imaging; 2020 Oct; 101(10):649-655. PubMed ID: 32654985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
    Choi BB; Kim SH
    Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.
    Chen JH; Yu H; Lin M; Mehta RS; Su MY
    Magn Reson Imaging; 2013 Nov; 31(9):1465-71. PubMed ID: 23992630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response.
    Preibsch H; Wanner L; Bahrs SD; Wietek BM; Siegmann-Luz KC; Oberlecher E; Hahn M; Staebler A; Nikolaou K; Wiesinger B
    Eur Radiol; 2016 Jun; 26(6):1590-6. PubMed ID: 26382845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
    Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
    Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
    Onishi N; Li W; Newitt DC; Harnish RJ; Strand F; Nguyen AA; Arasu VA; Gibbs J; Jones EF; Wilmes LJ; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard S; Umphrey HR; Nelson MT; Church AL; Bolan PJ; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez Paniagua D; Hardesty L; Brandt KR; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane E; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica LA; Niell B; Drukteinis J; Newell MS; Giurescu ME; Berman E; Lehman CD; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau SH; Chenevert T; Yau C; DeMichele A; Berry DA; Esserman LJ; Hylton NM
    Radiology; 2021 Nov; 301(2):295-308. PubMed ID: 34427465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy.
    Oh SJ; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
    Br J Radiol; 2018 Jul; 91(1088):20170550. PubMed ID: 29848015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
    De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
    Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
    Kim J; Han BK; Ko EY; Ko ES; Choi JS; Park KW
    Eur Radiol; 2022 Jun; 32(6):4056-4066. PubMed ID: 34989844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
    Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
    Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
    Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
    Yoon GY; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH; Kim JE; Kim SB
    Clin Breast Cancer; 2020 Feb; 20(1):25-32. PubMed ID: 31519449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
    Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
    Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation Between Preoperative Radiological and Postoperative Pathological Tumor Size in Patients With HER2
    Falcone V; Reiser E; Grula L; Bago-Horvath Z; Stolz M; Catic A; Deutschmann C; Singer C; Pfeiler G
    Clin Breast Cancer; 2022 Feb; 22(2):149-160. PubMed ID: 34229944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.